Brief Reports Open Access
Copyright ©The Author(s) 2000. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 15, 2000; 6(3): 451-453
Published online Jun 15, 2000. doi: 10.3748/wjg.v6.i3.451
Pathogenetic effects of platelet activating factor on enterogenic endotoxemia after burn
Pei-Wu Yu, Department of General Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Guang-Xia Xiao, Wei-Ling Fu, Jian-Cheng Yuan, Li-Xin Zhou and Xiao-Jian Qin, Institute of Burn Research, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Pei-Wu Yu, Department of General Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Telephone: +86-23-68754097
Received: January 11, 2000
Revised: February 3, 2000
Accepted: February 16, 2000
Published online: June 15, 2000

Abstract
Key Words: Platelet activating factor; burn; endotoxemia; intestinal permeability



INTRODUCTION

Previous clinical and experimental studies have indicated that an early endotoxemia occurred after a major burn. It is unlikely that burn wound sepsis is the source of circulating endotoxin in less than 12 h after burn. Increasing evidence demonstrates that the bacteria and endotoxin in the gastrointestinal tract can pass through the gut barrier into blood circulation to form enterogenic endotoxemia following burn[1-3]. However, its pathogenesis remains poorly understood. Platelet activating factor (PAF), an endogenous phospholipid mediator, has recently been proposed as a critical mediator in shock, sepsis and multiple organ failure[4,5]. In this study, the relationship between changes of PAF and enterogenic endotoxemia was observed on rat models with 30% TBSA III burn. The purpose was to investigate the pathogenetic effects of PAF on the occurrence of enterogenic endotoxemia after burn.

MATERIALS AND METHODS
Animals

Wistar rats, male or female, weighing 220 g ± 30 g were used, they were provided by Laboratory of Animal Experiment, Institute of Burn Research, Third Military Medical University.

Experimental design

Animals were randomly divided into three groups. Group 1 (n = 10): normal rats served as control. Group 2 (n = 40): burned rats that had undergone 30% TBSA III burn. Group 3 (n = 40): treated rats that received PAF antagonist WEB 2170 (5 mg/kg) by intraperitoneal injection after burn. WEB 2170 was provided by Boeringer Ingelheim Pharmac-euticals Inc, Germany.

Animals were killed on 6, 12, 24 and 48 h postburn. Blood and terminal ileum were obtained from all animals for assay of PAF and endotoxin.

Burn model

Rats were anesthetized intraperitoneally with ketamine hydrocloride 80 mL/kg body weight, and their backs were shaved. They were placed in a mould that left approximately 30% area of their body surface exposed. These exposed surface s were immersed in 92 °C water for 18 s. This type of burn injury is a full-thick ness burn. Animals were resuscitated with 40 mL/kg of lactated Ringer′s solution.

Measurement of PAF contents in blood and intestinal tissue

Blood (1 mL) was collected into polypropylene tube containing 5 mL of methanol. The methanolic extract was separated by centrifugation. The supernata nts were collected and chloroform and water were added to effect phase separation. The lower chloroform-rich phase contained all PAF activity. Chloroform was evaporated under a stream of nitrogen. The samples were stored under -20 °C. Segments of ileum tissue (200 mg) were added to 2 mL of 0.25% bovine serum albumin, and after homogenization, the mixture was added to 2 mL of cold acetone, and then centrifuged. Two mL of chloroform as added to the supernatants. After a further centrifugation, the thin layer chloroform containing PAF was collected and evaporated by nitrogen. PAF activity was bioassayed by the aggregation of rabbit washed platelets.

Measurement of intestinal mucosal permeability

After overnight fast, rats were anesthetized, a midline abdominal incision was made. Fifteen cm segments of ileum were isolated, cannulated proximally and distally, and perfused continuously with saline at rate of 1-2 mL/min. 99mTc DTPA (5.55-7.4 MBq/kg) was injected via the carotid vein and allowed to equilibrate for 30 min. After that, a 10 min perfusion fluid and 1 mL blood were collected for measurement of activity of 99mTc DTPA. The animals were killed and the perfused ileal segment was excised and weighed. DTPA clearance was calculated using the following formula: DTPA clearance = (cpm perfusate × Q)/(cpm plasma × W), and was expressed as mL/min·100 g. Where Q is the rate of perfusion; W, the weight of perfused ileum.

Measurement of plasma endotoxin

Plasma endotoxin was assayed with chromogenic limulus amebocyte lysate technique.

Statistical analysis

All data were expressed as -x±s, and statistical analyses were made using Student′s t test.

RESULTS
The changes of PAF content

PAF contents of blood and intestinal tissue in burn group were significantly higher than those in control group (P < 0.01). The peak level occurred at 12 h postburn. In PAF-antagonist treatment group, the PAF contents of blood and intestinal tissue were significantly decreased compared with burn group, but were higher than those in control group (Table 1).

Table 1 Levels of PAF in blood and intestinal tissue (-x±s).
GroupnAfter burn (h)
6122448
Control10
Blood (μg/L)0.56 ± 0.07
Intestine (ng/g)0.41 ± 0.06
Burn40
Blood (μg/L)1.72 ± 0.21b2.76 ± 0.25b1.54 ± 0.24 b1.19 ± 0.13b
Intestine (ng/g)1.80 ± 0.21b2.34 ± 0.18b1.68 ± 0.15b1.42 ± 0.16b
Treatment40
Blood (μg/L)0.84 ± 0.16da1.46 ± 0.27db0.93 ± 0.18ca0.71 ± 0.15c
Intestine (ng/g)0.67 ± 0.07da1.24 ± 0.13db0.83 ± 0.12da0.64 ± 0.08da
The changes of intestinal mucosal permeability

The intestinal mucosal permeability increased significantly at 6 h postburn and kept increasing during 48 h postburn compared with control group. The intestinal mucosal permeability in treatment group was lower than those in burn group (Table 2).

Table 2 Changes of intestinal mucosal permeability (mL·min-1·100 g-1, -x±s).
GroupnAfter burn (h)
6122448
Control100.07 ± 0.02
Burn400.33 ± 0.14b0.58 ± 0.18b0.21 ± 0.07b0.13 ± 0.04b
Treatment400.19 ± 0.05db0.27 ± 0.06db0.10 ± 0.04da0.08 ± 0.03c
The changes of plasma endotoxin

The levels of plasma endotoxin in burn group were significantly higher than those in control group. The levels of plasma endotoxin in treatment group were significantly lower than those in burn group (Table 3).

Table 3 Levels of plasma endotoxin (ng/L, -x±s).
GroupnAfter burn (h)
6122448
Control1034 ± 8
Burn4093 ± 28b129 ± 32b90 ± 22b59 ± 16b
Treatment4057 ± 15ca66 ± 13db50 ± 10da43 ± 8c
Correlation analysis

The correlations between intestinal PAF and intestinal mucosal permeability, blood PAF and plasma endotoxin, intestinal mucosal permeability and plasma endotoxin in burn group were analyzed. The results showed positive correlation among the above three pairs with P < 0.01, r = 0.94, 0.93 and 0.95 respectively.

DISCUSSION

The pathogenesis of enterogenic endotoxemia remains poorly understood. It is considered that the main cause is injury of intestinal mucosal barrier. Under physiological condition, the intestinal mucosa functions as a major local defense barrier preventing intestinal bacteria and endotoxin from invading distant organs and tissues. However, under the circumstances of trauma, shock and sepsis, the impairment of intestinal barrier may result from ischemic damage of the intestinal mucosa, the bacteria and endotoxin in gastrointestinal tract can pass through the intestinal barrier to mesenteric lymph nodes and systemic organs, resulting in enterogenic sepsis (endotoxemia)[6,7]. There is increasing evidence that enterogenic sepsis may play an important role in the development of systemic infection as well as multiple organ failure[8,9]. The present study results show that increased intestinal permeability after burn is an important cause of enterogenic endotoxemia.

PAF is a phospholipid mediator released from stimulated leukocytes, platelets, endothelial and mast cells[10,11]. It has been regarded as an important endogenous mediator of shock, sepsis and multiple organ failure. Our study demonstrated that PAF contents in blood and intestinal tissue after burn were all significantly increased and were positively correlated with the increase of intestinal permeability and plasma endotoxin. Treatment with PAF antagonist can significantly decrease intestinal permeability and plasma endotoxin. These suggest that PAF is involved in the process of increasing the intestinal permeability after burn and is also an important factor leading to enterogenic endotoxemia.

Previous studies showed that endotoxin can stimulate directly or indirectly macrophages and endothelial cells to release PAF, which also mediates some endotoxin-induced pathologic processes of multiple organ injury[12,13]. It is suggested that a PAF-endotoxin positive feedback relationship existed in the body. Therefore, administration of PAF antagonists has an important effect o n preventing and treating enterogenic endotoxemia.

Footnotes

Dr. Pei-Wu Yu, graduated from the Third Military Medical University in 1984, now associate professor of surgery, majoring in gastrointestinal surgery, having 28 papers published.

Project supported by the National Natural Science Foundation of China, No. 39290700.

Edited by You DY and Zhu LH

proofread by Sun SM

References
1.  Jones WG, Barber AE, Minei JP, Fahey TJ, Shires GT, Shires GT. Differential pathophysiology of bacterial translocation after thermal injury and sepsis. Ann Surg. 1991;214:24-30.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  LeVoyer T, Cioffi WG, Pratt L, Shippee R, McManus WF, Mason AD, Pruitt BA. Alterations in intestinal permeability after thermal injury. Arch Surg. 1992;127:26-29; discussion 29-30.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Gianotti L, Braga M, Vaiani R, Almondo F, Di Carlo V. Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies. Burns. 1996;22:120-124.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Anderson BO, Bensard DD, Harken AH. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet. 1991;172:415-424.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Beyer AJ, Smalley DM, Shyr YM, Wood JG, Cheung LY. PAF and CD18 mediate neutrophil infiltration in upper gastrointestinal tract during intra-abdominal sepsis. Am J Physiol. 1998;275:G467-G472.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Wilmore DW, Smith RJ, O'Dwyer ST, Jacobs DO, Ziegler TR, Wang XD. The gut: a central organ after surgical stress. Surgery. 1988;104:917-923.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Fink MP. Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med. 1991;19:627-641.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Fukushima R, Gianotti L, Alexander JW, Pyles T. The degree of bacterial translocation is a determinant factor for mortality after burn injury and is improved by prostaglandin analogs. Ann Surg. 1992;216:438-444; discussion 444-445.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257-277.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 1990;259:C697-C708.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Kubes P, Arfors KE, Granger DN. Platelet-activating factor-induced mucosal dysfunction: role of oxidants and granulocytes. Am J Physiol. 1991;260:G965-G971.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Torley LW, Pickett WC, Carroll ML, Kohler CA, Schaub RE, Wissner A, DeJoy SQ, Oronsky AL, Kerwar SS. Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob Agents Chemother. 1992;36:1971-1977.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 12]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
13.  Fletcher JR, DiSimone AG, Earnest MA. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg. 1990;211:312-316.  [PubMed]  [DOI]  [Cited in This Article: ]